Battle For Europe: API Producers Make Headway In Brussels On Drug Safety Regulations | May 16, 2011 Issue - Vol. 89 Issue 20 | Chemical & Engineering News
Volume 89 Issue 20 | p. 13
Issue Date: May 16, 2011

Cover Stories: Shock To The System

Battle For Europe: API Producers Make Headway In Brussels On Drug Safety Regulations

Department: Government & Policy, Business
Keywords: Europe, EFCG, pharmaceutical, API
Hovione’s Villax has taken up the cause for domestic and international inspections.
Credit: Rick Mullin/C&EN
Hovione’s Villax has taken up the cause for domestic and international inspections.
Credit: Rick Mullin/C&EN

For Guy Villax, chief executive officer of Hovione, a Portuguese supplier of active pharmaceutical ingredients, the shock of recognition came at a 2004 meeting of the Active Pharmaceutical Ingredients Committee, a European trade group known as APIC. “I heard somebody say there is no legal requirement to meet current Good Manufacturing Practice standards for APIs in Europe,” he says.

The implications were clear for a firm operating under cGMP, the U.S. Food & Drug Administration’s quality guideline, he says. “It meant that idiots like Hovione are throwing money out the window to reduce patient risk while all kinds of people are exploiting the fact that there are no requirements.” Digging further, Villax learned that European regulatory authorities inspect plants only in Europe. “This kind of dropped on me like a bombshell,” he recalls.

Villax joined a battle that was already under way at APIC, where Chris Oldenhof, manager of external regulatory affairs at DSM and currently the group’s president, was leading the push to change the laws in Europe. Oldenhof and Tony Scott, former director of the U.K.’s Chemical Industries Association and adviser to the European Fine Chemicals Group (EFCG), met with the regulators in Brussels to lobby for the cGMP standard and comprehensive inspections—changes that would help level the playing field for firms already meeting the standards.

“The people in Brussels thought these guys were coming from Mars,” Villax recalls. “They said, ‘What are these guys saying? We haven’t seen any problems. We think that the regulatory environment in Europe and regulatory compliance are hunky-dory.’ We couldn’t get anyone in the European Medicines Agency or the commission interested in the red flag we were waving.”

Oldenhof confirms his group’s uphill battle. “In Europe,” he says, “everything is complicated.” Regulatory authority resides with European Union member states. The European Medicines Agency, Oldenhof explains, lacks the central authority of FDA to oversee plant inspections.

API producers managed to score a first victory in 2005, Oldenhof says, when Europe adopted a cGMP standard established by the International Conference on Harmonisation, a coalition of national standard-setting bodies. Earlier this year, the European Parliament issued a more comprehensive directive guarding against the shipment of falsified APIs into its member nations.

Under the Falsified Medicines Directive, which was issued in February, shipments of APIs must include a statement from health authorities in the country of origin that the product was manufactured according to cGMP standards or the equivalent. The directive requires European API manufacturers to register with national health authorities and outlines an auditing regimen for suppliers outside the EU. It also establishes a public database on cGMP certification. The directive is expected to be adopted by member states later this year.

EFCG’s Scott agrees that dealing with European regulators has been a struggle, partly because of the fragmented enforcement structure but also because of the difficulties of explaining the pharmaceutical industry supply chain.

He says EFCG, which was formed in 2004 to promote enforcement of quality standards in the drug industry, has had an easier time dealing with regulators in the U.S. EFCG has worked with its U.S. counterpart, the Society of Chemical Manufacturers & Affiliates, to lobby Congress for enhanced international inspections. Villax testified in hearings before the U.S. Congress in 2006.

“But Europe is listening now,” Scott says. EFCG launched an effort this year to establish cGMP standards for excipients and to certify excipient suppliers.

“I think momentum is building,” Oldenhof says. The key, he says, is establishing joint industry and regulatory oversight of the supply chain. “There is money to be made by falsifying pharmaceuticals,” he says. “And if you have no oversight or deterrence, it will happen. It’s a law of nature.”

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment